MOONLAKE IMMUNOTHERAPEUTICS (MLTX) Operating cash flow 2021–2025
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$196.0MFY2025 · since FY2021: -$611,071 → -$196.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$196.0M | -68.1% |
| FY2024 | -$116.6M | -172.5% |
| FY2023 | -$42.8M | +23.5% |
| FY2022 | -$55.9M | -9046.9% |
| FY2021 | -$611,071 | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More MLTX financial trends
MLTX RevenueMLTX Net incomeMLTX Net marginMLTX Gross profitMLTX Gross marginMLTX Operating incomeMLTX Operating marginMLTX Free cash flowMLTX Capital expendituresMLTX Return on equityMLTX Stock buybacksMLTX Dividends paidMLTX Total assetsMLTX Total liabilitiesMLTX Shareholders’ equityMLTX overview →